Highest-materiality recent filing
Aptevo annual meeting: both director nominees elected, all four proposals approved
Zs. Harsanyi re-elected director: 216,997 for, 17,454 withheld; Barbara Lopez Kunz: 211,050 for, 23,401 withheld.
Aptevo Q2: mipletamig 81% remission in AML; Niowave 50/50 radiopharma deal
Cash $9.8M at June 30, 2026; raised $0.6M under Yorkville SEPAs in Q2.
Aptevo raises $4.5M via warrant exercise and PIPE at $4.03/share
Exercised existing warrants for 254,922 shares at $4.03; issued inducement warrants for 1,274,610 shares.
Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone; new solid tumor strategy
Patent filing covers proprietary Nectin-4 x PD-L1 dual-targeting backbone for solid tumors.
Aptevo awarded $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling studies
Grant of $1,499,951 from Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling studies for APVO451, a trispecific antibody targeting nectin-4, CD40, and CD3 for solid tumors.
Aptevo (APVO) partners with Niowave for radiopharma development; Niowave takes 7.9% equity stake
50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs using Aptevo's multispecific platforms and Niowave's radioisotopes.
Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured
Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.
Aptevo Reports 87% Clinical Benefit Rate and 81% Remission in Frontline AML Trial RAINIER
Across 31 evaluable frontline AML patients, mipletamig combo showed 87% clinical benefit rate and 81% remission (CR/CRi), outperforming VIALE-A benchmark of 66.4%.
Aptevo FY2025 net loss $26M, cash $21.6M; mipletamig 86% CBR in AML; CEO transition
Mipletamig triplet in 28 frontline AML patients: 86% CBR, 79% CR/CRi, no CRS observed.
Aptevo reports 86% clinical benefit rate for mipletamig combo in frontline AML, zero CRS
Mipletamig + venetoclax + azacitidine showed 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients.
Aptevo shareholders approve issuance of >19.99% of common stock to Yorkville
Shareholders approved issuance of more than 19.99% of outstanding common stock under Standby Equity Purchase Agreement with Yorkville.
Marvin White retires as Aptevo CEO; COO Jeff Lamothe named successor effective April 1, 2026
White to become Executive Chair; Lamothe promoted from COO to President and CEO and appointed to Board.
Aptevo secures $60M equity line with Yorkville, extends funding runway into 2029
Enters $60M Standby Equity Purchase Agreement with Yorkville; minimal fees, no warrants.
Aptevo Therapeutics files 1-for-18 reverse stock split effective Dec 29, 2025
Reverse split ratio 1-for-18 approved by board Dec 17; effective Dec 29 at 5:01 PM ET.
Aptevo reports mipletamig 93% ORR, zero CRS in frontline AML Phase 1b/2 trial at ASH 2025
100% of patients free of cytokine release syndrome (CRS) across cohorts 1-3.
Aptevo reports 89% remission in frontline AML with mipletamig; Q3 net loss $7.5M
89% of evaluable frontline AML patients achieved remission (CR+CRi) across two trials of mipletamig; no cytokine release syndrome observed.
Aptevo extends shareholder rights agreement Final Expiration Date to Oct 29, 2026
Amendment No. 5 to Rights Agreement extends Final Expiration Date from Nov 2025 to Oct 29, 2026.
Aptevo reports 100% remission rate in Cohort 3 of Phase 1b/2 RAINIER trial for mipletamig in AML
100% remission rate (CR/CRi) in Cohort 3 with mipletamig + venetoclax + azacitidine for newly diagnosed AML unfit for intensive chemo.
Aptevo expands oncology pipeline with two new trispecific candidates APVO452 and APVO451
Filed provisional patents for APVO452 (PSMA x CD3 x CD40) targeting prostate cancer and APVO451 (Nectin-4 x CD3 x CD40) for multiple solid tumors.
Aptevo Q2 net loss $6.2M; mipletamig 85% remission in AML; pipeline expands with APVO455
Net loss $6.2M for Q2 2025; cash $9.4M as of June 30, 2025.
Aptevo shareholders approve reverse stock split and Yorkville equity issuance
Elected directors Marvin L. White (443,945 for) and John E. Niederhuber (444,661 for) to board.
Aptevo regains Nasdaq compliance with $15.9M equity raise
Received Nasdaq notice confirming compliance with minimum $2.5M stockholders' equity rule.
Raised approx. $15.9M via four equity transactions: April 4 ($2.1M), April 22 ($2.0M), June 20 ($8.0M), and ATM facility ($3.8M).
Aptevo Therapeutics appoints Baker Tilly as new auditor after Moss Adams merger
Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned and Baker Tilly appointed for FY2025.
Aptevo raises $8M, reports 85% remission for mipletamig in AML, adds APVO455
Gross proceeds of ~$8M from registered direct offering of 2.465M shares/pre-funded warrants and 12.325M common warrants at $3.25/unit.
Aptevo files prospectus supplement for ATM offering of up to $8.0M
Filed prospectus supplement for ATM offering of up to $8,037,381 in common stock via Roth Capital Partners.
Aptevo Therapeutics enters $25M standby equity purchase agreement with Yorkville
Up to $25M in common stock may be sold to YA II PN over 36 months at 96% of lowest 3-day VWAP.
Aptevo Therapeutics effects 1-for-20 reverse stock split effective May 23, 2025
Stockholders approved reverse split 1:6 to 1:20 at May 14 special meeting; board chose 1:20 on May 21.
Aptevo receives Nasdaq delisting notice for equity deficiency; announces 1-for-20 reverse split
Nasdaq notified Aptevo of non-compliance with $2.5M stockholders' equity rule; deficit of $1.473M as of March 31, 2025.
Aptevo reports 90% remission rate in frontline AML with mipletamig triplet; no CRS
9 of 10 frontline AML patients achieved remission with mipletamig + venetoclax + azacitidine across two trials.
Aptevo files prospectus supplement to sell up to $3.17M in common stock via ATM
ATM offering of up to $3,167,548 in common stock under sales agreement with Roth Capital Partners.
Aptevo enters ATM equity facility up to $2.96M; reports preliminary Q1 cash of $2.1M
Entered ATM sales agreement with Roth Capital to sell up to $2,959,952 in common stock; Roth receives 3.0% commission.
Aptevo raises $2.0M in registered direct offering at $0.862/share
Sold 2,324,000 shares at $0.862 each, gross proceeds ~$2.0M; net ~$1.8M after fees.
Aptevo raises $2.1M in registered direct offering and private placement; existing warrants amended
Sold 1,764,710 shares of common stock and warrants to purchase up to 3,529,420 shares at $1.19/unit.
Two additional AML patients achieve remission in Cohort 2 of RAINIER trial; 90% response rate
Two additional AML patients in Cohort 2 of RAINIER trial achieved remission within 30 days of treatment.
Mipletamig RAINIER Cohort 1: 100% of patients achieved remission within 30 days, including one MRD-negative status.
Aptevo Therapeutics provides pipeline update via investor presentation
Presentation highlights clinical candidates mipletamig and ALG.APV-527.
Aptevo: 100% remission in Cohort 1 of mipletamig frontline AML trial; 2 of 3 patients MRD-negative
100% of patients (3/3) achieved remission within 30 days in Cohort 1 of RAINIER Phase 1b trial.
Aptevo raises up to $6.2M via warrant exercise inducement; issues new warrants at $9.53
Holders exercise up to 823,544 existing warrants at $7.50/share for ~$6.2M gross proceeds.
Aptevo unveils preclinical bispecific APVO442 for prostate cancer; targets $14B market
APVO442 is a PSMA x CD3 bispecific antibody designed to treat prostate cancer.
Aptevo Therapeutics completes 1-for-37 reverse stock split effective December 3, 2024
Certificate of Amendment filed with Delaware; split effective at 5:01 p.m. ET on December 3, 2024.
Aptevo's Peter Pavlik to present ADAPTIR platform at Pep Talk; new molecule expected in early 2025
Peter Pavlik, PhD, will chair a 'Bi and Multispecific Biologics' session at Pep Talk conference in January 2025.
Aptevo highlights bispecific pipeline; first AML patient shows 90% blast reduction
First patient in Phase 1b/2 RAINIER trial for mipletamig achieved 90% leukemic blast reduction within 30 days.
Aptevo reports first RAINIER trial patient achieved 90% leukemic blast reduction in 30 days
First patient in Phase 1b/2 RAINIER trial achieved 90% reduction in leukemic blasts within first 30 days.
Aptevo Q3 net loss $5.1M; cash $7.8M; initiates RAINIER trial for AML
Net loss of $5.1M ($0.48 per share) in Q3 2024 vs $6.3M ($22.16) in Q3 2023.
Aptevo Therapeutics extends poison pill expiration to Oct 2025, adjusts purchase price to $70
Amendment No. 4 extends Rights Agreement Final Expiration Date to October 31, 2025.
Aptevo shareholders approve reverse stock split (1:5–1:37) and dilutive stock issuance
Stock issuance and warrant proposal passed (593,301 For, 412,901 Against, 5,355 Abstain).
Aptevo raises $3.0M via registered direct offering of stock and warrants at $0.33/share
Issued 9,090,910 shares or pre-funded warrants plus warrants for up to 18,181,820 shares at $0.33 per unit.
Aptevo/Alligator Phase 1 ALG.APV-527 trial: 60% stable disease, 11+ month duration in breast cancer
Phase 1 data presented at ESMO: 9 of 15 evaluable patients (60%) achieved stable disease across solid tumors.
Aptevo posts Q2 net loss $5.9M, cash $8.1M; APVO436 Phase 1b/2 trial to begin
Net loss of $5.9M ($1.67/sh) vs $7.9M ($53.95/sh) in Q2 2023; R&D spend down 33% to $3.6M.
On March 3, 2023, Aptevo Therapeutics Inc. (the “Company”) appointed Jeffrey G. Lamothe, formerly the Company’s Executive Vice President, Chief Financial Officer, to Executive Vice President, Chief Operating Officer.
Also, on March 3, 2023, the Company appointed Daphne Taylor, formerly the Company’s Senior Vice President, Finance, to Senior Vice President, Chief Financial Officer.
On January 21, 2022, Fuad El-Hibri, Chairman of the Board of Directors (“Board”) of Aptevo Therapeutics Inc. (“Company”), notified the Company of his retirement and resignation as a director of the Company, effective April 1, 2022.
On January 21, 2022, the Board appointed John Niederhuber, M.D. as Chairman of the Board effective April 1, 2022.
On August 25, 2021, Jane Gross (“Gross”) resigned as the Chief Scientific Officer of Aptevo Therapeutics Inc. (the “Company”) effective September 14, 2021 (“Separation Date”)
Max materiality 0.90 · Median 0.65 · Most common event other_material